Background. Although it is widely accepted that adults with immunocompromising conditions
are at greatly increased risk of pneumococcal infection, the extent of risk among …

Abstract Background. In 2012/2013, a single dose of 13-valent pneumococcal conjugate
vaccine (PCV13) was recommended for immunocompromised adults in the United States …

Clin Microbiol Infect 2012; 18 (Suppl. 5): 7–14 Abstract Streptococcus pneumoniae causes
different types of acute, invasive and non‐invasive clinical infections, being the most …

To overview the present global burden of pneumococcal disease is important because new
preventive measures such as the pneumococcal conjugate vaccine 13 are currently being …

Children with previously identified at-risk/high-risk conditions remain at elevated risk of
pneumococcal disease in the era of widespread use of pneumococcal conjugate vaccine …

Background The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the
US childhood immunization schedule in 2000 has substantially reduced the incidence of …

Background Despite the widespread availability of pneumococcal vaccines, rates of
pneumococcal disease are disproportionately high in adults with chronic and …

Background Incidence, manifestations and case-fatality rate (CFR) of invasive
pneumococcal disease (IPD) vary with age and comorbidities. New vaccines, changing age …

Use of the pneumococcal conjugate vaccines among children in the US since 2000 has
dramatically reduced pneumococcal disease burden among adults. Significant vaccine …

Background The burden of invasive pneumococcal disease in young children decreased
dramatically following introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) …